Monday, September 29, 2025 9:51:50 PM
Well there are some significant risks with Lupkynis .
eGFR ( kidney function ) typically declines in the first 3 mths then recovers in most ...but not all. Some patients have ended up with worse kidney function ...small number I think .
Theres also issues with elevated blood pressure and hyperkalemia in some and its only supposed to be prescribed to those with a eGFR over 45 .
As with many new drugs ...problems show up a year or two after approval ...once its used by the wider population .
Wife only knows of 2 patients on it and they monitor them fairly closely I think
Its very expensive with significant prior approval hurdles
Any bearing on UNCY ...well OLC is a reformulation of Fosrenol thats been used for years by thousands ...so less likely ( but not nonexistent ) .
Co may be required to have some kind of registry ...like ICU pediatric ...but doubt it would be more than that
JMO
Kiwi
eGFR ( kidney function ) typically declines in the first 3 mths then recovers in most ...but not all. Some patients have ended up with worse kidney function ...small number I think .
Theres also issues with elevated blood pressure and hyperkalemia in some and its only supposed to be prescribed to those with a eGFR over 45 .
As with many new drugs ...problems show up a year or two after approval ...once its used by the wider population .
Wife only knows of 2 patients on it and they monitor them fairly closely I think
Its very expensive with significant prior approval hurdles
Any bearing on UNCY ...well OLC is a reformulation of Fosrenol thats been used for years by thousands ...so less likely ( but not nonexistent ) .
Co may be required to have some kind of registry ...like ICU pediatric ...but doubt it would be more than that
JMO
Kiwi
Recent UNCY News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/06/2026 01:11:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/30/2026 11:29:20 AM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/30/2026 10:32:02 AM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 02/10/2026 06:15:05 PM
- Unicycive shares gain as FDA accepts resubmitted OLC NDA • IH Market News • 01/29/2026 03:01:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2025 10:10:14 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/14/2025 10:09:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2025 02:12:01 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/12/2025 11:39:29 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/28/2025 11:30:13 AM
- UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit • PR Newswire (US) • 10/14/2025 06:55:00 AM
- Unicycive Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - UNCY • PR Newswire (US) • 10/02/2025 12:04:00 PM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Unicycive Therapeutics, Inc.(UNCY) Shareholders • PR Newswire (US) • 09/29/2025 12:45:00 PM
- Unicycive Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – UNCY • Business Wire • 09/25/2025 07:19:00 PM
